Clinical Trial Update: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for BGB-43395, evaluating it alone or in combination therapies in Chinese participants with HR+/HER2- breast cancer and other adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• BGB-43395

Snippet

Sponsor: BeiGene | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: ACTIVE_NOT_RECRUITING